Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Sulindac Recombinant Mouse Monoclonal Antibody (1B11)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Sulindac Antibody (MA566296) in SDS-PAGE
SDS-PAGE characterization of Sulindac under reducing conditions. Lane M: Protein marker (kDa); Lane SLD: Purified Sulindac Recombinant Monoclonal (Product # MA566296). Sulindac showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-658.
产品信息
MA566296
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
1B11
抗原
Conjugate of SLD hapten and KLH.
偶联物
形式
Liquid
浓度
10 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has demonstrated significant anticancer activity, particularly through its active metabolite, sulindac sulfide. Structurally, sulindac is an indene derivative, and its analogs have been synthesized to enhance its therapeutic profile. These analogs include amide derivatives and nitric oxide-donating compounds, which have been evaluated for their antitumor activity across various cancer cell lines, including prostate, colon, and breast cancer. Sulindac sulfide acts as a gamma-secretase modulator, offering potential benefits in triple-negative breast cancer models without immune suppression. The drug's mechanism involves COX inhibition, although some analogs are designed to reduce COX-related inhibition while maintaining antitumor efficacy. Sulindac's gene location and specific molecular interactions are subjects of ongoing research, focusing on its binding modes with COX-1 and COX-2 enzymes.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
